Evidence map›Paper›PMID 39422800›Full record

Observational studyJournal of patient-reported outcomes2024

Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy.

Josephine J Koldenhof, Bernice O Akpobome, Danielle Zweers, Stance Klaasse, Saskia C C M Teunissen, Petronella O Witteveen, Karijn P M Suijkerbuijk, Alexander de Graeff, Frederieke H van der Baan

Abstract readObservational StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of patient-reported outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Josephine J KoldenhofDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands. j.koldenhof@umcutrecht.nl.ORCID 0000-0003-4205-6611
Bernice O AkpobomeCenter of Expertise in Palliative Care, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands.
Danielle ZweersDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands.
Stance KlaasseDepartment of Haematology, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands.
Saskia C C M TeunissenCenter of Expertise in Palliative Care, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands.
Petronella O WitteveenDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands.
Karijn P M SuijkerbuijkDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands.
Alexander de GraeffDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands.
Frederieke H van der BaanDepartment of Medical Oncology, University Medical Centre Utrecht, University Utrecht, (room B02.225), PO Box 85500, Utrecht, 3584 CX, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Utrecht Symptom Diary (USD) is a validated Dutch patient-reported outcome measurement (PROM) tool - based on the Edmonton Symptom Assessment System - to assess and monitor symptoms in cancer patients. The USD contains 11 items concerning frequently occurring symptoms in cancer patients (pain, sleeping problems, dry mouth, dysphagia, lack of appetite, abnormal stool, nausea, shortness of breath, fatigue, anxiety and depressed mood) and an item on overall well-being. For the outpatient USD 11 items concerning frequently occurring signs and symptoms in patients receiving chemotherapy and/or targeted therapy were added to the USD: taste alteration, oral pain, weight loss, diarrhoea, hair changes, skin problems, nail problems, eye problems, tingling, concentration problems and problems with sexuality. This current study aimed to evaluate the 11 added items on this treatment specific outpatient USD in cancer patients receiving intravenous chemotherapy and/or targeted therapy.

methodsObservational longitudinal retrospective cohort study including all adult outpatients with cancer receiving intravenous chemotherapy and/or targeted therapy in an academic hospital in the Netherlands who completed at least one outpatient USD as part of routine care (2012-2021). Relevance, comprehensiveness as well as criterion and construct validity were assessed.

results1733 patients who completed ≥ 1 outpatient USD during intravenous chemotherapy and/or targeted therapy were included for analysis. Relevance as well as comprehensiveness of the items on the outpatient USD in this patient population was shown. Criterion validation was demonstrated for all added items of the outpatient USD - except for the item on oral pain. An additional analysis showed that mouth problems were detected with both outpatient USD items oral pain and dry mouth. Construct validity was demonstrated for the items hair changes and skin and nail problems. Construct validity on eye problems was not tested due to the low number of paired outpatient USDs.

conclusionsThe treatment specific outpatient USD is a validated PROM in outpatients with cancer receiving intravenous chemotherapy and/or targeted therapy. Considering its validity in this broad group of patients, we think the treatment-specific outpatient USD is widely applicable. In addition to providing tailored supportive symptom care, the USD-data can be used to increase knowledge about symptom burden in daily practice in this population.

Indexed as

NeoplasmsOutpatientsPatient Reported Outcome MeasuresAdultAgedAntineoplastic AgentsFemaleHumansLongitudinal StudiesMaleMiddle AgedNetherlandsQuality of LifeReproducibility of ResultsRetrospective StudiesSymptom AssessmentAntineoplastic AgentsCancerChemotherapyPatient-reported outcome measurementSupportive careSymptom assessmentTargeted therapy

Identifiers

PMID39422800
PMCPMC11489364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.